Clelia Donisi

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna et al. · Clinical Lung Cancer · 2020 · 82 citations · Full text

Pd-l1 Expression, Clinical Epidemiology, Immunology +8

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

Giuseppe Luigi Banna, Alessio Cortellini, Diego Cortinovis et al. · ESMO Open · 2021 · 61 citations · Full text

Smoking status during first‐line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A case–control matched analysis from a large multicenter study

Alessio Cortellini, Andrea De Giglio, Katia Cannita et al. · Thoracic Cancer · 2021 · 47 citations · Full text

Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer

Clelia Madeddu, Sı́lvia Busquets, Clelia Donisi et al. · Cancers · 2023 · 40 citations · Full text

Immunotherapy and Cancer: The Multi-Omics Perspective

Clelia Donisi, Andrea Pretta, Valeria Pusceddu et al. · International Journal of Molecular Sciences · 2024 · 27 citations · Full text

Cancer Treatment Approaches, Immunology, Biological Microenvironments +19